



## Antibiotics Currently in Clinical Development

As of December 2014, an estimated 37 new antibiotics<sup>1</sup> that have the potential to treat serious bacterial infections are in clinical development for the U.S. market. The success rate for drug development is low; at best, only 1 in 5 candidates that enter human testing will be approved for patients.\* This snapshot of the antibiotic pipeline will be updated periodically as products advance or are known to drop out of development. Please contact Rachel Zetts at rzetts@pewtrusts.org or 202-540-6557 with additions or updates.

Drug name	Development phase <sup>2</sup>	Company	Drug class	Cited for potential activity against Gram-negative pathogens? <sup>3</sup>	Known QIDP <sup>4</sup> designation?	Potential indication(s) <sup>5</sup>
Tedizolid (Sivextro)	Approved June 20, 2014	Cubist Pharmaceuticals	Oxazolidinone		Yes	<b>Approved for: acute bacterial skin and skin structure infections; other potential indications: hospital-acquired bacterial pneumonia/ventilator-acquired bacterial pneumonia</b>
Dalbavancin (Dalvance)	Approved May 23, 2014	Actavis (formerly Durata Therapeutics)	Lipoglycopeptide		Yes	<b>Approved for: acute bacterial skin and skin structure infections; other potential indications: community-acquired bacterial pneumonia</b>
Oritavancin (Orbactiv)	Approved Aug. 6, 2014	The Medicines Company	Glycopeptide		Yes	<b>Approved for: acute bacterial skin and skin structure infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA)</b>
Ceftolozane+Tazobactam (Zerbaxa)	Approved Dec. 19, 2014	Cubist Pharmaceuticals	Novel cephalosporin+beta-lactamase inhibitor	Yes	Yes	<b>Approved for: complicated urinary tract infections, complicated intra-abdominal infections, acute pyelonephritis (kidney infection); other potential indications: hospital-acquired bacterial pneumonia/ventilator-associated pneumonia</b>
Ceftazidime+Avibactam (CAZ-AVI)	New Drug Application (NDA) submitted (for complicated urinary tract infections and complicated intra-abdominal infections)	AstraZeneca/Actavis (formerly Forest Laboratories)	Cephalosporin + novel beta-lactamase inhibitor	Yes	Yes	<b>Complicated urinary tract infections, complicated intra-abdominal infections, acute pyelonephritis (kidney infection), hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia</b>
OP0595 (RG 6080)	Phase 1 <sup>10</sup>	Meiji Seika Pharma Co. Ltd./Fedora Pharmaceuticals Inc. (Roche licensee) <sup>12</sup>	Beta-lactamase inhibitor	Yes		Bacterial infections